FIELD: medicine.
SUBSTANCE: invention relates to a compound corresponding to the general formula (I), where X is N, CH; R1 is selected from a group including -CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7-element)heterocycloalkyl containing 1-2 heteroatoms selected from nitrogen, oxygen, (5-element) heteroaryl containing 1-3 heteroatoms selected from nitrogen, oxygen, sulfur, where the specified (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7-element)heterocycloalkyl, (5-element)heteroaryl is optionally substituted with one or more substituents independently selected from R6; R2 is selected from a group including halogen, (C1-C4)alkyl and (C3-C7)cycloalkyl, where the specified (C1-C4)alkyl and (C3-C7)cycloalkyl are optionally substituted with one or two substituents independently selected from halogen; R3 is selected from a group including (C1-C4)alkyl; R4 is selected from a group including (C1-C4)alkyl; R5 is selected from a group including (C1-C6)alkyl, (C3-C7)cycloalkyl, phenyl and -ORa, where the specified (C1-C6)alkyl, (C3-C7)cycloalkyl, phenyl and -ORa are optionally substituted with one or more substituents independently selected from R7; R6 is a group including -OH, -CN, halogen, =O, -S(O)2Rb, -NRcRd, -C(O)Rb, (C1-C4)alkyl, hydroxy(C1-C4)alkyl, ORb, (C3-C6)cycloalkyl; R7 is a group including halogen, (C1-C4)alkyl; Ra is (C1-C6)alkyl; Rb is (C1-C6)alkyl; each Rc and Rd is independently H, (C1-C6)alkyl; or its pharmaceutically acceptable salts. The invention also relates to compounds of the general formula (II) and (IX), where R2 is selected from a group including halogen and (C1-C4)alkyl, where the specified (C1-C4)alkyl is optionally substituted with one or two substituents independently selected from halogen; R3 is selected from (C1-C4)alkyl; R4 is selected from a group of (C1-C4)alkyl; R5 is selected from a group including (C1-C6)alkyl, (C3-C7)cycloalkyl, phenyl and -ORa, where the specified (C1-C6)alkyl, (C3-C7)cycloalkyl, phenyl and -ORa are optionally substituted with one or more substituents independently selected from halogen; Ra is selected from (C1-C6)alkyl. The invention relates to a pharmaceutical composition with a modulating effect of ROR-gamma, containing effective amount of the compound of the formula (I), together with a pharmaceutically acceptable base or auxiliary substance or a pharmaceutically acceptable carrier(s).
EFFECT: heteroaromatic compounds for use in the treatment of a disease, disorder or condition, where the disease, disorder or condition is sensitive to ROR-gamma modulation.
20 cl, 2 tbl, 83 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| 1,3,4-OXADIAZOLE SULPHAMIDE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2695227C1 |
| SULPHONAMIDE COMPOUND OR SALT THEREOF | 2017 |
|
RU2732572C2 |
| COMPOSITIONS CONTAINING BENZOPIPERAZINE AS BROMODOMAIN BET INHIBITORS | 2014 |
|
RU2720237C2 |
| COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | 2015 |
|
RU2767460C2 |
| NEW COMPOUNDS AND COMPOSITIONS FOR CATHEPSIN INHIBITION | 2004 |
|
RU2346943C2 |
| SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | 2014 |
|
RU2675105C9 |
| IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2695664C1 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| NONSTEROIDAL MODULATORS OF GLUCOCORTICOID RECEPTORS FOR LOCAL DRUG DELIVERY | 2016 |
|
RU2731618C2 |
